Published in Chinese Journal of Contemporary Pediatrics
目的 探讨微小残留病（MRD）在不同融合基因背景的急性B淋巴细胞白血病（B-ALL）患儿中的临床意义。 方法 回顾性分析2008年1月至2015年4月融合基因阴性（336例）、融合基因 ETV6-RUNX1 阳性（79例）、融合基因 E2A-PBX1 阳性（26例）的B-ALL患儿共441例的临床资料。采用流式细胞术检测MRD，分析3组患儿在诱导治疗第15天（TP1）、第33天（TP2）、第12周（TP3）的MRD对预后的影响。 结果 在融合基因阴性患儿中，TP1、TP2、TP3时，MRD阳性组总生存（OS）率、无事件生存（EFS）率均显著低于MRD阴性组（ P 0.05）。 结论 在B-ALL患儿中，融合基因阴性患儿的MRD对预后提示意义最为明确，而 ETV6-RUNX1 阳性患儿和 E...
Published in Chemotherapy
Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients at high risk of relapse. Real-time quantitative PCR allows MRD to be measured with high sensitivity in CBF-AML. If the patient ...
Published in Cancer treatment reviews
In this article, we broadly review the application of cfDNA analysis to the diagnosis and management of lymphoma. We introduce the advantages of cfDNA measurement over conventional tissue biopsy and describe how cfDNA may be utilized for both genotyping and detection of minimal residual disease. First, we discuss genotyping, beginning with differen...
Published in Bioscience Reports
Monitoring of early-stage breast cancer is critical in promptly addressing disease relapse. Circulating cell-free DNA provides a minimally invasive and sensitive means to probing the disease. In a longitudinal analysis of 250 patients with early breast cancer, we compared the circulating cell-free DNA recovered from both plasma and urine specimens....
Published in Translational oncology
At the onset, few cancer cells amidst the tumor bulk, identified as cancer stem cells (CSCs) or early disseminated cancer cells (eDCCs) are capable of survival post conventional therapy and persist as minimal residual disease (MRD). Metastatic subclones emerge both early and late in the life of primary tumor ensuing an ongoing regional clonal evolu...
Published in Clinical lymphoma, myeloma & leukemia
Immunoglobulin light chain (AL) amyloidosis results from clonal plasma cell (PC)-derived immunoglobulin light chain-mediated end-organ dysfunction, the extent and severity of which predicts survival. Anti-PC therapies reduce clonal light chain burden, which usually results in improvement of organ function, and consequently overall survival. Respons...
Published in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profil...
ABSTRACT Background: The minimal residual disease (MRD) is the most important prognostic factor for acute lymphoblastic leukemia (ALL) in children. This study aimed to investigate the influence of detecting the MRD by the multiparametric flow cytometry (MFC) at day 15 (D15) of the induction on the analysis of the risk group classifications of the d...
Published in Journal of Hematology & Oncology
The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in deter...
Published in Current Treatment Options in Oncology
Liquid biopsy using blood components to assess circulating tumor DNA (ctDNA) is rapidly becoming a new standard-of-care technology in many tumor types, including breast cancer, due to the potential to provide predictive and prognostic information. The minimally invasive and repeatable nature of plasma based mutational testing is appealing for patie...
